研究单位：[1]Eli Lilly and Company[2]First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China,650032[3]Xuanwu Hospital-Capital Medical University Beijing,Beijing,China,100053[4]The First Affiliated Hospital Chongqing Medical University Chongqing,Chongqing,China,400016[5]Guangzhou First People's Hospital Guangzhou,Guangdong,China,510180[6]The Affiliated Hospital of Guiyang Medical College Guiyang,Guizhou,China,550004[7]The First Affiliated Hospital of Zhengzhou Universtiy Zhengzhou,Henan,China,450052[8]Tongji Hosp Tongji Med Col Huazhong Univ of Sci & Tech Wu Han,Hubei,China,430030[9]Wuhan Union Hospital Wuhan,Hubei,China,430022[10]Xiangya Hospital,Central South University Changsha,Hunan,China,410008
研究目的：
The reason for this study is to see if the drug galcanezumab is safe and effective in participants with episodic migraine. The study will last about 53 weeks and may include up to 12 visits.
